In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

Importance Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable
(MSS) or mismatch repair–proficient (pMMR) colorectal cancer. Recent findings suggest the …

Circulating tumor DNA (ctDNA), ie, DNA shed from tumor cells into the bloodstream, is
emerging as one of the most useful plasma biomarkers in patients with multiple types of …

The rapid adoption of immune checkpoint blockade (ICB) therapies has led to a need to
understand the mechanistic drivers of efficacy and the identification of novel biomarkers that …

Purpose We aimed to investigate the role of ubiquilin-4 in predicting the immunotherapy
response in gastric cancer. Methods Retrospective RNA-sequencing and …

Circulating cell-free DNA (cfDNA) in the blood of cancer patients contains tumor-specific
mutated genes and viral genome that can be identified and quantified as 'tumor-specific …

Highlights•TMB has been proposed as a biomarker of ICI efficacy across cancers, but its use
in the clinic remains elusive.•Technical and biological factors limit the accuracy of TMB for …

Colorectal cancer (CRC) remains a significant global health challenge, ranking among the
leading causes of cancer-related morbidity and mortality worldwide. Recent advancements …

Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering Not
all TMB assays are the same: Clinical validity of robust algorithmic germline filtering Cancer …

Background The efficacy of pembrolizumab monotherapy in metastatic castration-resistant
prostate cancer patients (mCRPC) when stratified by MSI-H and/or TMB-H is poorly defined …